Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin: Twelve-Week Post-treatment Follow-up

Abstract

Get full access to this article

View all access options for this article.

References

DeCarolis

Westanmo

Chen

Boese

Walquist

Rector

TS.

Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin. Annals of Pharmacotherapy. 2016; 50(11):909-917.

Soriano

Labarga

Barreiro

. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol. 2015;11:333-341.

US Food and Drug Administration. Harvoni® prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205834s010lbl.pdf. Accessed November 18, 2016.

Britnell

Willets

Vanderman

Woodard

Britt

RB.

Influence of successful chronic hepatitis C virus treatment with ledipasvir/sofosbuvir on warfarin dosing requirements in four veterans. Pharmacotherapy. 2016;36:1173-1179.

Halkin

Shapiro

Kurnik

Loebstein

Shalev

Kokia

Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching. Clin Pharmacol Ther. 2003;74:215-221.